REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.
Also called NCT07213778
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,000 participants
- Sponsor
- Registry
-
NCT07213778 -
2025-520479-25-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Greece, Malaysia, Moldova, Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT07213778. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-24 (actual); primary completion 2027-05-17 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
- Acronym
- ROXI-ASPEN
- Condition
- Symptomatic Venous Thromboembolism (VTE)
- Intervention (Drug)
- REGN7508
- Intervention (Drug)
- Acetylsalicylic Acid (ASA)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07213778- Content hash
7f1801d54ed89576e244be5e716260300c0c23730a13d5b694e3dd25bd611466